Research suggests that GLP-1s, a type of weight-loss drug, may be associated with a lower risk of breast cancer. Some studies have found a link between GLP-1 use and reduced breast cancer incidence, although the exact relationship between the two is still being investigated. Further research, including clinical trials, is being conducted to better understand the potential cancer benefits and risks of GLP-1s.